Wells Fargo
NBIX icon

Wells Fargo’s Neurocrine Biosciences NBIX Stock Holding History

Wells Fargo’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-25,000
Closed -$235K – 6591
2019
Q2 		$235K Buy
+25,000
New +$2.05M ﹤0.01% 4884

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Wells Fargo's NBIX Position: Q2 2026 in Review

Wells Fargo increased its Neurocrine Biosciences (NBIX) stake by 9.4% in Q2 2026, buying an estimated $3.22M and bringing the position to 253,026 shares worth $42.6M. The position accounts for 0.01% of the portfolio, ranked #1132.

Wells Fargo first reported a position in NBIX in Q2 2013 and has held it in 53 quarters since. The position peaked at $127M in Q3 2018. 779 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Wells Fargo held 253,026 shares of Neurocrine Biosciences worth $42.6M as of Q2 2026.
  • Wells Fargo bought 21,715 Neurocrine Biosciences shares in Q2 2026, an estimated $3.22M.
  • Neurocrine Biosciences made up 0.01% of Wells Fargo's portfolio in Q2 2026, its #1132 holding.
  • Wells Fargo first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 53 quarters since.
  • Wells Fargo's Neurocrine Biosciences position peaked at $127M in Q3 2018.
  • 779 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.